The most common keywords used in the most recent research papers are semaglutide, obesity, T2DM, diabetes mellitus type 2 and glucagon-like peptide-1, glucagon-like peptide-1 receptor agonist, antidiabetic agent, liraglutide, and cardiovascular disease. This evidence concerns the gene GLP1R and cardiovascular disorder.